Mannkind Corp.
- MNKD ยท Nasdaq
- Pharmaceutical Preparations
- Danbury, CT
- 592 employees
- CIK 0000899460
Updated from SEC filings through
Top things to know
Executives
- Michael Castagna Chief Executive Officer 4, 2026-07-17
- Christopher B. Prentiss Chief Financial Officer 4, 2026-07-17
- Ajay Ahuja Chief Medical Officer 4, 2026-03-25
- Stuart A. Tross, Ph.D. Executive Vice President, Human Resources 10-K, 2026-02-26
- Dominic Marasco, R.Ph. President, Endocrine Business Unit 10-K, 2026-02-26
-
David Thomson EVP Genl Counsel & Secretary 4, 2026-07-17
What leadership is saying
“The third quarter marked an important transition for MannKind as we shifted from delivering on three major catalysts to executing against them”
Earnings press release (8-K Ex. 99.1), filed November 5, 2026
Mannkind Corp is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Danbury, CT. It trades as MNKD on Nasdaq. Revenue was $349M in the fiscal year ending December 31, 2025, +22.2% from the year before. It reported about 592 employees. Michael Castagna is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $349M 10-K, 2026-02-26 | $286M 10-K, 2026-02-26 | $199M 10-K, 2026-02-26 | $99.8M 10-K, 2025-02-26 | $75.4M 10-K, 2024-02-27 |
| Operating income | $38.8M 10-K, 2026-02-26 | $72.6M 10-K, 2026-02-26 | $8.7M 10-K, 2026-02-26 | -$64.1M 10-K, 2025-02-26 | -$47.0M 10-K, 2024-02-27 |
| SG&A | $144M 10-K, 2026-02-26 | $94.3M 10-K, 2026-02-26 | $94.3M 10-K, 2026-02-26 | $91.5M 10-K, 2025-02-26 | $77.4M 10-K, 2022-02-24 |
| Net income | $5.9M 10-K, 2026-02-26 | $27.6M 10-K, 2026-02-26 | -$11.9M 10-K, 2026-02-26 | -$87.4M 10-K, 2025-02-26 | -$80.9M 10-K, 2024-02-27 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Michael Castagna Chief Executive Officer, MannKind (NASDAQ: MNKD) | Chief Executive Officer | 4, 2026-07-17 |
| Christopher B. Prentiss Chief Financial Officer | Chief Financial Officer | 4, 2026-07-17 |
| David B. Thomson | Named in proxy bio: Executive Vice President, General Counsel and Secretary | DEF 14A, 2026-04-07 |
| Ajay Ahuja Biopharmaceutical physician-executive redesigning medicines around the patient experience, with a personal mission to transform the treatment of heart failure. | Chief Medical Officer | 4, 2026-03-25 |
| Stuart A. Tross, Ph.D. | Executive Vice President, Human Resources | 10-K, 2026-02-26 |
| Dominic Marasco, R.Ph. | President, Endocrine Business Unit | 10-K, 2026-02-26 |
| David Thomson Corporate Vice President and General Counsel at MannKind Corporation | EVP Genl Counsel & Secretary | 4, 2026-07-17 |
 Sanjay R. Singh Executive Vice President - Tech Operations | EVP Technical Operations | 4, 2026-07-17 |
| Dominic Marasco | Pres, Endocrine Business Unit | 4, 2026-07-17 |
 James S. Shannon, M.D. | Board member (per proxy) bio: Chairman of the Board of Directors | DEF 14A, 2026-04-07 |
| JAMES S. SHANNON, M.D., MRCP (UK) | Board member (per proxy) bio: Chair of the Board of Directors | DEF 14A, 2026-04-07 |
 Michael A. Friedman, M.D. | director | 10-K, 2026-02-26 |
 Ronald J. Consiglio | director | 10-K, 2026-02-26 |
 Steven B. Binder | Director | 10-K, 2026-02-26 |
| Anthony Hooper | director | 10-K, 2026-02-26 |
| Christine Mundkur | director | 10-K, 2026-02-26 |
What Mannkind Corp does
We are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, we aim to deliver therapies designed to fit seamlessly into daily life.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 321.6 million (as of October 23, 2026) | 10-Q, November 5, 2026 |
|---|---|---|
| Public float | $1.1B (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 5, 2026 |
| Latest proxy statement | Meeting April 7, 2026 (filed April 7, 2026) | DEF 14A, April 7, 2026 |
| Auditor | Deloitte & Touche LLP (Los Angeles, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 25, 2026 | Steven B. Binder Director | Sale | 39,051 | $128K | Form 4, September 28, 2026 |
| September 10, 2026 | Steven B. Binder Director | Sale | 33,558 | $128K | Form 4, September 14, 2026 |
| August 7, 2026 | Steven B. Binder Director | Sale | 39,051 | $159K | Form 4, August 10, 2026 |
| July 17, 2026 | David Thomson EVP Genl Counsel & Secretary | Sale | 24,109 | $98K | Form 4, July 17, 2026 |
| July 17, 2026 | Steven B. Binder Director | Sale | 52,485 | $213K | Form 4, July 17, 2026 |
| May 12, 2026 | Steven B. Binder Director | Sale | 16,940 | $56K | Form 4, May 13, 2026 |
| May 12, 2026 | David Thomson EVP Genl Counsel & Secretary | Sale | 3,033 | $10K | Form 4, May 13, 2026 |
| March 10, 2026 | Michael Castagna Chief Executive Officer | Buy | 100,000 | $259K | Form 4, March 10, 2026 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-21
- Item 8.01 Other events
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-24
- Item 3.02 Unregistered sales of equity securities
- Item 8.01 Other events
- 8-K filed 2026-06-02
- Item 8.01 Other events
- 8-K filed 2026-05-28
- Item 8.01 Other events
- 8-K filed 2026-05-22
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-26
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-10
- Item 8.01 Other events
Frequently asked questions about Mannkind Corp
- What does Mannkind Corp do?
- In its own words, from Item 1 of its 10-K: "We are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, we aim to deliver therapies designed to fit seamlessly into daily life."
- What is Mannkind Corp's revenue?
- $349M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Mannkind Corp profitable?
- Mannkind Corp reported net income of $5.9M for the fiscal year ending December 31, 2025.
- How many employees does Mannkind Corp have?
- About 592, as stated in its annual report.
- Who is the CEO of Mannkind Corp?
- Michael Castagna, Chief Executive Officer, as named in a 4 filed July 17, 2026.
- Who is the CFO of Mannkind Corp?
- Christopher B. Prentiss, Chief Financial Officer, as named in a 4 filed July 17, 2026.
- Where is Mannkind Corp headquartered?
- Danbury, CT.
- What is Mannkind Corp's stock ticker?
- MNKD on Nasdaq.
- What industry is Mannkind Corp in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Mannkind Corp's website?
- mannkindcorp.com.
- When does Mannkind Corp report earnings next?
- February 3, 2027. Source: estimate_8k_pattern.
- Is Mannkind Corp a public company?
- Yes. Mannkind Corp files with the SEC under CIK 0000899460 and trades as MNKD.
- Who audits Mannkind Corp?
- Deloitte & Touche LLP, Los Angeles, California, as named in its latest annual report (10-K).
- How many shares of Mannkind Corp are outstanding?
- 321.6 million shares as of October 23, 2026, from its 10-Q filed November 5, 2026.
- What is Mannkind Corp's public float?
- $1.1B as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Mannkind Corp report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 5, 2026.
- When is Mannkind Corp's annual shareholder meeting?
- April 7, 2026, per its proxy statement (DEF 14A) filed April 7, 2026.
- Have Mannkind Corp insiders traded stock recently?
- Since July 16, 2025, officers and directors reported 16 open-market sales worth about $3.8M and 1 purchase worth about $259K on Forms 4 and 5. The most recent: Steven B. Binder (Director) sold 39,051 shares on September 25, 2026.